サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1667794

ヘルパンギーナ治療の世界市場レポート 2025年

Herpangina Treatment Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ヘルパンギーナ治療の世界市場レポート 2025年
出版日: 2025年02月28日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヘルパンギーナ治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で26億8,000万米ドルに成長します。予測期間の成長は、ウイルス株の出現、小児医療への注目の高まり、国際的な保健規制、診断における技術革新、ヘルスケアアクセスの改善などに起因しています。予測期間の世界の動向には、口腔病変に対する局所療法の開発、診断と相談のための遠隔医療の統合、患者教育と意識向上プログラムの強化、臨床試験と研究のための連携、国際保健対策への取り組みなどが含まれます。

ヘルパンギーナ治療市場の成長は、研究開発活動の増加によって牽引されると予測されます。ヘルパンギーナは、主に小児が罹患するウイルス感染症で、咽頭や扁桃腺に痛みを伴うただれや潰瘍を生じ、一般的にコクサッキーウイルスやエンテロウイルスが原因となります。ヘルパンギーナの治療は、水疱、高熱、口や喉の不快感、流涎、食欲不振などの症状を緩和することを目的としています。例えば、2024年4月、英国の国家統計機関であるOffice for National Statisticsによると、英国政府の研究開発に対する純支出は、2021年の140億ポンド（177億米ドル）に対し、2022年は155億ポンド（195億米ドル）と10.5％増加しました。このように、研究開発活動の活発化がヘルパンギーナ治療市場の成長に寄与しています。

ヘルパンギーナ治療市場の成長は、小児人口の増加によっても促進されると予想されます。出生から思春期または成熟期までの個人を包含するこの人口セグメントは、ヘルパンギーナ治療において症状管理、支持療法、適切な水分補給の確保に焦点を当てた特別な注意を必要とします。連邦児童・家族統計機関間フォーラムによると、2022年の米国の小児人口は約7,250万人で、2050年には7,820万人に増加すると予測されています。このような小児人口の増加は、ヘルパンギーナ治療市場の成長を大きく促進する要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界ヘルパンギーナ治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界のヘルパンギーナ治療市場：成長率分析
  • 世界のヘルパンギーナ治療市場の実績：規模と成長, 2019-2024
  • 世界のヘルパンギーナ治療市場の予測：規模と成長, 2024-2029, 2034F
  • 世界ヘルパンギーナ治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のヘルパンギーナ治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 局所麻酔薬
  • イブプロフェンまたはアセトアミノフェン
  • その他の治療法
  • 世界のヘルパンギーナ治療市場ウイルスによる、実績と予測, 2019-2024, 2024-2029F, 2034F
  • コクサッキーウイルスA
  • コクサッキーウイルスB
  • エンテロウイルス71
  • エコーウイルス
  • 世界のヘルパンギーナ治療市場症状別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 高熱
  • 喉の痛み
  • 喉や口の水疱や潰瘍
  • 嚥下困難
  • 食欲不振
  • 首の痛み
  • リンパ節の腫れ
  • 頭痛
  • 世界のヘルパンギーナ治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • ホームケア
  • 専門クリニック
  • その他のエンドユーザー
  • 世界のヘルパンギーナ治療市場、局所麻酔薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ベンゾカイン
  • リドカイン
  • その他の麻酔薬
  • 世界のヘルパンギーナ治療市場イブプロフェンまたはアセトアミノフェンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • イブプロフェン
  • アセトアミノフェン
  • その他の治療法
  • 世界のヘルパンギーナ治療市場抗ウイルス薬の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
  • コルチコステロイド
  • 支持療法

第7章 地域別・国別分析

  • 世界のヘルパンギーナ治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界のヘルパンギーナ治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ヘルパンギーナ治療市場：競合情勢
  • ヘルパンギーナ治療市場：企業プロファイル
    • Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Mucocort
  • Aurena Laboratories AB
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila
  • Aurobindo Pharma Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • ヘルパンギーナ治療市場2029：新たな機会を提供する国
  • ヘルパンギーナ治療市場2029：新たな機会を提供するセグメント
  • ヘルパンギーナ治療市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r24199

Herpangina treatment involves managing the symptoms of the viral illness that commonly affects children, causing painful sores or ulcers on the tonsils and the back of the throat. Treatment focuses on alleviating symptoms and supporting the body's natural healing process, as herpangina is a viral infection that typically resolves on its own without the need for specific antiviral medications.

The main types of herpangina treatment include topical anesthetics, ibuprofen or acetaminophen, and others. Topical anesthetics are a form of local anesthesia applied to the skin's surface or mucous membrane to temporarily numb the affected region. Herpangina is caused by viruses such as coxsackie virus A, coxsackie virus B, enterovirus 71, and echovirus, leading to various symptoms such as high fever, sore throat, blisters or ulcers in the throat and mouth, difficulty swallowing, loss of appetite, headache, neck pain, and swollen lymph glands. These treatments are utilized by various end-users, including hospitals, home care settings, specialty clinics, and others.

The herpangina treatment market research report is one of a series of new reports from The Business Research Company that provides herpangina treatment market statistics, including herpangina treatment industry global market size, regional shares, competitors with a herpangina treatment market share, detailed herpangina treatment market segments, market trends and opportunities, and any further data you may need to thrive in the herpangina treatment industry. This herpangina treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The herpangina treatment market size has grown strongly in recent years. It will grow from$1.86 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to viral outbreaks and prevalence, pediatric population growth, healthcare infrastructure development, public health awareness programs, clinical research and treatment advancements

The herpangina treatment market size is expected to see strong growth in the next few years. It will grow to $2.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to emerging viral strains, increasing focus on pediatric health, international health regulations, technological innovations in diagnostics, healthcare access improvements. Major trends in the forecast period include development of topical therapies for oral lesions, integration of telemedicine for diagnosis and consultation, enhanced patient education and awareness programs, collaborations for clinical trials and research, global health preparedness initiatives.

The growth of the herpangina treatment market is anticipated to be driven by an increase in research and development activities. Herpangina is a viral infection that primarily affects children, leading to painful sores or ulcers in the throat and tonsils, typically caused by coxsackievirus and enteroviruses. Treatments for herpangina aim to alleviate symptoms such as blisters, high fever, mouth or throat discomfort, drooling, and loss of appetite. For instance, in April 2024, the Office for National Statistics, a UK-based national statistical agency, reported that the UK government's net expenditure on research and development increased by 10.5% in 2022, amounting to £15.5 billion ($19.5 billion), compared to £14.0 billion ($17.7 billion) in 2021. Thus, the rise in research and development activities is contributing to the growth of the herpangina treatment market.

The growth of the herpangina treatment market is also expected to be fueled by the increasing pediatric population. This population segment, encompassing individuals from birth to adolescence or maturity, requires specific attention in herpangina treatment, focusing on symptom management, supportive care, and ensuring proper hydration. The Federal Interagency Forum on Child and Family Statistics reported around 72.5 million children in the United States in 2022, with a projected increase to 78.2 million by 2050. This rise in the pediatric population is a significant driver for the growth of the herpangina treatment market.

The growth of the herpangina treatment market is expected to be propelled by a surge in healthcare expenditure. Healthcare expenditure encompasses all costs related to health services, nutrition activities, family planning, and emergency aid designated for health. An increase in healthcare spending can contribute to the expansion of resources and the availability of trained healthcare professionals for herpangina treatment. According to the Centers for Medicare & Medicaid Services, the National Health Expenditure (NHE) increased by 2.7% to $4.3 trillion in 2021, reaching $12,914 per person. Projected annual increases of 5.1 percent and a 19.6 percent share of GDP in 2030 indicate sustained growth in healthcare expenditure, driving the herpangina treatment market.

The development of treatments for herpangina-related diseases, such as aphthous stomatitis, is a notable trend gaining traction in the herpangina treatment market. Major companies in the market are actively working on therapies to alleviate pain in individuals with recurrent mouth ulcers. For instance, in September 2022, Mucocort, a Sweden-based healthcare company, partnered with Aurena Laboratories AB to create a unique self-absorbing pain relief patch for individuals suffering from recurrent mouth ulcers and aphthous stomatitis, facilitating pain relief and accelerating the natural healing process.

Key players in the herpangina treatment market are focusing on the development of new treatments, including Acetaminophen pain relief products for adults. These products, containing acetaminophen as the active ingredient, aim to relieve pain and reduce fever. In April 2022, Genexa, a US-based pharmaceutical company, introduced 'Genexa Acetaminophen Extra Strength' and 'Acetaminophen PM caplets' for temporary relief from minor aches, discomfort associated with conditions such as the common cold, headaches, backaches, arthritis pain, toothaches, muscular aches, and premenstrual and menstrual cramps. The launch of such products contributes to the diversification and growth of the herpangina treatment market.

Major companies operating in the herpangina treatment market include Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc, AstraZeneca, Novartis AG, GlaxoSmithKline Plc, Merck & Co., Inc., AbbVie Inc., Eli Lilly and Company, Bayer AG, Sanofi, Bristol-Myers Squibb Company, Johnson & Johnson, Mucocort, Aurena Laboratories AB, Cipla Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Aurobindo Pharma Ltd., Lupin Limited, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Sandoz International GmbH, Endo International plc, Mylan N.V., CSL Limited.

North America was the largest region in the global herpangina treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpangina treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the herpangina treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The herpangina treatment market consists of revenues earned by entities by providing medical services such as symptomatic relief, hydration, soft diet, and oral hygiene. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Herpangina Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on herpangina treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for herpangina treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The herpangina treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Topical Anesthetics; Ibuprofen Or Acetaminophen; Other Treatments
  • 2) By Virus: Coxsackie Virus A; Coxsackie Virus B; Enterovirus 71; Echovirus
  • 3) By Symptoms: High Fever; Sore Throat; Blisters Or Ulcers In The Throat Mouth; Difficulty Swallowing; Loss Of Appetite; Neck Pain; Swollen Lymph Glands; and Headache
  • 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Subsegments:
  • 1) By Topical Anesthetics: Benzocaine; Lidocaine; Other Anesthetics
  • 2) By Ibuprofen or Acetaminophen: Ibuprofen; Acetaminophen; Other Treatments
  • 3) By Antiviral Medications: Corticosteroids; Supportive Care
  • Companies Mentioned: Hoffmann-La Roche Ltd.; Takeda Pharmaceutical Company Limited; Pfizer Inc; AstraZeneca; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Herpangina Treatment Market Characteristics

3. Herpangina Treatment Market Trends And Strategies

4. Herpangina Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Herpangina Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Herpangina Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Herpangina Treatment Market Growth Rate Analysis
  • 5.4. Global Herpangina Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Herpangina Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Herpangina Treatment Total Addressable Market (TAM)

6. Herpangina Treatment Market Segmentation

  • 6.1. Global Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Anesthetics
  • Ibuprofen Or Acetaminophen
  • Other Treatments
  • 6.2. Global Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Coxsackie Virus A
  • Coxsackie Virus B
  • Enterovirus 71
  • Echovirus
  • 6.3. Global Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • High Fever
  • Sore Throat
  • Blisters Or Ulcers In The Throat Mouth
  • Difficulty Swallowing
  • Loss Of Appetite
  • Neck Pain
  • Swollen Lymph Glands
  • and Headache
  • 6.4. Global Herpangina Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users
  • 6.5. Global Herpangina Treatment Market, Sub-Segmentation Of Topical Anesthetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Benzocaine
  • Lidocaine
  • Other Anesthetics
  • 6.6. Global Herpangina Treatment Market, Sub-Segmentation Of Ibuprofen or Acetaminophen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ibuprofen
  • Acetaminophen
  • Other Treatments
  • 6.7. Global Herpangina Treatment Market, Sub-Segmentation Of Antiviral Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Corticosteroids
  • Supportive Care

7. Herpangina Treatment Market Regional And Country Analysis

  • 7.1. Global Herpangina Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Herpangina Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Herpangina Treatment Market

  • 8.1. Asia-Pacific Herpangina Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Herpangina Treatment Market

  • 9.1. China Herpangina Treatment Market Overview
  • 9.2. China Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Herpangina Treatment Market

  • 10.1. India Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Herpangina Treatment Market

  • 11.1. Japan Herpangina Treatment Market Overview
  • 11.2. Japan Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Herpangina Treatment Market

  • 12.1. Australia Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Herpangina Treatment Market

  • 13.1. Indonesia Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Herpangina Treatment Market

  • 14.1. South Korea Herpangina Treatment Market Overview
  • 14.2. South Korea Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Herpangina Treatment Market

  • 15.1. Western Europe Herpangina Treatment Market Overview
  • 15.2. Western Europe Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Herpangina Treatment Market

  • 16.1. UK Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Herpangina Treatment Market

  • 17.1. Germany Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Herpangina Treatment Market

  • 18.1. France Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Herpangina Treatment Market

  • 19.1. Italy Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Herpangina Treatment Market

  • 20.1. Spain Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Herpangina Treatment Market

  • 21.1. Eastern Europe Herpangina Treatment Market Overview
  • 21.2. Eastern Europe Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Herpangina Treatment Market

  • 22.1. Russia Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Herpangina Treatment Market

  • 23.1. North America Herpangina Treatment Market Overview
  • 23.2. North America Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Herpangina Treatment Market

  • 24.1. USA Herpangina Treatment Market Overview
  • 24.2. USA Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Herpangina Treatment Market

  • 25.1. Canada Herpangina Treatment Market Overview
  • 25.2. Canada Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Herpangina Treatment Market

  • 26.1. South America Herpangina Treatment Market Overview
  • 26.2. South America Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Herpangina Treatment Market

  • 27.1. Brazil Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Herpangina Treatment Market

  • 28.1. Middle East Herpangina Treatment Market Overview
  • 28.2. Middle East Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Herpangina Treatment Market

  • 29.1. Africa Herpangina Treatment Market Overview
  • 29.2. Africa Herpangina Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Herpangina Treatment Market, Segmentation By Virus, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Herpangina Treatment Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Herpangina Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Herpangina Treatment Market Competitive Landscape
  • 30.2. Herpangina Treatment Market Company Profiles
    • 30.2.1. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Herpangina Treatment Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline Plc
  • 31.2. Merck & Co., Inc.
  • 31.3. AbbVie Inc.
  • 31.4. Eli Lilly and Company
  • 31.5. Bayer AG
  • 31.6. Sanofi
  • 31.7. Bristol-Myers Squibb Company
  • 31.8. Johnson & Johnson
  • 31.9. Mucocort
  • 31.10. Aurena Laboratories AB
  • 31.11. Cipla Inc.
  • 31.12. Dr. Reddy's Laboratories Ltd.
  • 31.13. Teva Pharmaceutical Industries Ltd.
  • 31.14. Zydus Cadila
  • 31.15. Aurobindo Pharma Ltd.

32. Global Herpangina Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Herpangina Treatment Market

34. Recent Developments In The Herpangina Treatment Market

35. Herpangina Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Herpangina Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Herpangina Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Herpangina Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer